WO2013109051A1 - Composition for improving memory or concentration containing extract fraction with increased content of ginseng-derived ginsenoside rg3 as active ingredient - Google Patents

Composition for improving memory or concentration containing extract fraction with increased content of ginseng-derived ginsenoside rg3 as active ingredient Download PDF

Info

Publication number
WO2013109051A1
WO2013109051A1 PCT/KR2013/000337 KR2013000337W WO2013109051A1 WO 2013109051 A1 WO2013109051 A1 WO 2013109051A1 KR 2013000337 W KR2013000337 W KR 2013000337W WO 2013109051 A1 WO2013109051 A1 WO 2013109051A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginseng
ginsenoside
extract
composition
fraction
Prior art date
Application number
PCT/KR2013/000337
Other languages
French (fr)
Korean (ko)
Inventor
김영은
홍은영
서용기
이진희
Original Assignee
씨제이제일제당(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120154126A external-priority patent/KR20130085935A/en
Application filed by 씨제이제일제당(주) filed Critical 씨제이제일제당(주)
Publication of WO2013109051A1 publication Critical patent/WO2013109051A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a method for preparing an extract fraction of which ginsenoside Rg3 content derived from ginseng is enhanced and a composition for enhancing memory or concentration containing the same as an active ingredient.
  • Ginseng (Panax ginseng CA Mayer) is botanically belonging to the genus Araliaceae ginseng, which has been used for medicinal purposes in China since BC, and has been used for trade and medicinal use in Korea since the Three Kingdoms. It is widely used as a herbal medicine or health food.
  • Ginseng contains about 3 to 6% of ginsenosides called ginsenosides, and about 33 kinds of ginsenosides have been reported as ginsenosides.
  • Ginsenosides of ginseng are linked to high molecular weight components, which are not easily absorbed by the body after ingestion. That is, the ginsenoside form in which the sugar bound to the ginsenoside is decomposed is finally absorbed into the body and exhibits the physiological activity of each of the ginsenosides.
  • ginsenosides Rg3, Rh1, Rh2, etc. in ginseng have been reported to have excellent effects such as cancer prevention, cancer cell growth suppression, blood pressure lowering, cerebral nerve cell protection, antithrombotic action, and antioxidant action.
  • the ginsenosides Rg3, Rh1, Rh2 and the like are not detected in ginseng or ginseng, and the components are ginsenosides Rb1, Rb2, Rc, Rd, Rg1, Re, etc. contained in the ginseng during heat or It is converted and produced by pressure (Park Man-Gi et al., Ingredient analysis of new processed ginseng, 46th Fall Conference of Korean Pharmaceutical Society, 1997).
  • Red ginseng the most representative processed form of fresh ginseng, is washed clean with water, steamed for a certain period of time using heated steam in a certain container, and then dried by hot air firstly. Processed by drying until the content is about 12.5 to 13.5%.
  • the manufacturing process of the red ginseng is an inefficient process that consumes a lot of time and money, and has become a factor that inhibits the popularization of red ginseng.
  • Degradation of brain function can cause a variety of problems in all age groups, especially for the elderly, not only normal life due to brain damage such as dementia, but also across medical, social and economic aspects. It is not only a serious national health problem that must be recognized as a national important problem that needs to be solved urgently, but also brain function such as memory and concentration are more important areas of prevention than treatment after the onset, so the development of substances that can strengthen brain function is urgent. Reached.
  • the present inventors studied ginseng fraction extract for improving, preventing and treating memory or concentration decrease, and in particular, a method for preparing ginseng fraction extract with an increased trace component ginsenoside Rg3 component showing an excellent effect on enhancing brain function.
  • the inventors have invented a composition for preventing or improving a decrease in memory or concentration which contains the extract as an active ingredient.
  • Another object of the present invention is to provide a health functional food composition for improving memory or concentration which contains an extract fraction of ginsenoside Rg3 content as an active ingredient.
  • Still another object of the present invention is to provide a pharmaceutical composition for preventing and treating memory loss or concentration loss, which contains an extract fraction of which ginsenoside Rg3 content is enhanced as an active ingredient.
  • the object of the present invention is to obtain a ginseng extract using water or alcohol as an extraction solvent; Fractionating the substrate ginsenoside from the extract using an adsorptive resin; The substrate ginsenoside fraction was adjusted to pH 2-3 and then processed to a temperature ranging from 95 to 121 ° C. and a pressure ranging from 1 to 2 Kpa to obtain an extract fraction with enhanced ginsenoside Rg3 content. .
  • the present invention has an effect of providing a method for producing an extract fraction with enhanced ginsenoside Rg3 content using only water and alcohol to increase the stability and to reduce the manufacturing process cost due to the reduction of extraction time.
  • the present invention has an excellent effect of providing a health functional food composition for improving memory or concentration and a pharmaceutical composition for preventing and treating memory loss or concentration loss, which contains an extract fraction with increased ginsenoside Rg3 content as an active ingredient. have.
  • Figure 1 is a schematic diagram showing the overall manufacturing process of the extract fraction enhanced ginsenoside Rg3 content of the present invention.
  • Figure 3 is a diagram showing the HPLC chromatogram of the extract fraction enhanced ginsenoside Rg3 content of the present invention.
  • Figure 4 is a result showing the effect of the ginsenoside Rg3 content of the present invention on the spatial learning ability of the enhanced extract fraction.
  • ginseng does not simply refer to dried ginseng, but is used as a generic term for white ginseng, ginseng, red ginseng, taegeuk ginseng, black ginseng, stabilized ginseng, culture ginseng, and the like.
  • 'substrate ginsenoside' is used to mean all of ginsenosides Rb1, Rb2, Rc and Rd, which are substrates for the preparation of ginsenoside Rg3.
  • the extract fraction of the present invention ginsenoside Rg3 content obtained by the production method of the present invention can be safely used in the manufacture of food and pharmaceuticals.
  • the time and temperature for extracting the substrate ginsenoside from ginseng are not particularly limited as long as the substrate ginsenoside component is not destroyed, but is preferably extracted three times at 80 ° C. for 4 hours.
  • the adsorbent resin is not particularly limited as long as it can adsorb the substrate ginsenoside, but is preferably a diion HP20 adsorbent resin (Mitsubishi, Japan).
  • the non-saponin-based component is removed from the ginseng extract using 5 times the volume of resin as the mobile phase, and then 50 to 100 v / v% alcohol is used as the mobile phase. Elution of the substrate ginsenoside component was used as a substrate for preparing an extract of which the Rg3 component of the present invention is enhanced.
  • the obtained substrate ginsenoside fraction is adjusted to pH 2-3 by acid, followed by treatment at 95-121 ° C. with 1-2 Kpa, preferably 1.5 KPa.
  • the kind of acid is not particularly limited, and a preferred kind of acid is citric acid, acetic acid and the like.
  • the treatment converts the substrate ginsenosides to ginsenoside Rg3.
  • the extract fraction preferably contains 0.1 to 99% by weight relative to the total weight of the pharmaceutical composition.
  • the pharmaceutical composition according to the present invention may be prepared in various forms including pharmaceutically acceptable carriers, for example, oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and the like. It may be formulated in the form of sterile injectable solutions. Especially preferably, it may be formulated in an oral dosage form.
  • oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and the like. It may be formulated in the form of sterile injectable solutions. Especially preferably, it may be formulated in an oral dosage form.
  • the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. Also included are diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like.
  • Oral solid preparations include tablets, pills, powders, granules, capsules and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or lactose. ), Gelatin, and the like, and may include a lubricant such as magnesium stearate, talc, and the like.
  • Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include water, diluents such as liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like.
  • Parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and ethylol. Injectable esters such as late and the like.
  • aqueous solvents such as olive oil, and ethylol.
  • Injectable esters such as late and the like.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycero gelatin and the like can be used.
  • the present invention provides a pharmaceutical composition containing the extract fraction of the ginsenoside Rg3 content prepared according to the present invention as an active ingredient.
  • the extract fraction preferably contains 0.1 to 99% by weight based on the total weight of the health functional food composition.
  • the food composition of the present invention can be used as a dietary supplement.
  • health functional food means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functionality” refers to the structure of the human body. And ingestion for the purpose of obtaining nutrients for function or for obtaining useful effects in health uses such as physiological actions.
  • the food composition of the present invention may include a conventional food additives, and the suitability as the "food additives", unless otherwise specified, in accordance with the General Regulations and General Test Methods of the Food Additives approved by the Food and Drug Administration Judge according to the standards and standards for the item.
  • Food Additives Revolution examples include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid, natural additives such as color pigments, licorice extract, crystalline cellulose, high color pigments, guar gum, And mixed preparations such as sodium L-glutamate, algae additives, preservatives and tar dyes.
  • chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid
  • natural additives such as color pigments, licorice extract, crystalline cellulose, high color pigments, guar gum
  • mixed preparations such as sodium L-glutamate, algae additives, preservatives and tar dyes.
  • the hard capsules may be prepared by filling a conventional hard capsule with a mixture of additives such as an excipient or the like, or granules or exfoliated granules thereof, and a soft capsule agent with an excipient, etc. It can be prepared by filling a mixture with an additive of a capsule base such as gelatin.
  • the soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
  • the dietary supplement in cyclic form can be prepared by molding a mixture of excipients, binders, disintegrants, etc. in the herbal extracts in a suitable manner, and if necessary, the coating is carried out with white sugar or other suitable coating agent, or with starch, talc or a suitable substance. You may be greeted.
  • the health functional food in the form of granules may be prepared into granules in a suitable manner by mixing a mixture of an excipient, a binder, a disintegrant, and the like with the herbal extract, and may contain a flavoring agent, a copper, and the like as necessary.
  • the term definitions of the excipients, binders, disintegrants, glidants, copulation agents, flavoring agents, etc. of the present invention are described in documents known in the art and include those having the same or similar functions. Sacrament, Korean College of Pharmacy, 5 revised edition, p33-48, 1989).
  • the raw material used in the experiment of the present invention was extracted by refluxing three times at 80 ° C. for 4 hours by adding 10 times (w / v) water of 100 kg of the raw material using white rice, which is a root root of ginseng, as a test material.
  • the liquid chromatography (hereinafter referred to as "LC") value of the component obtained by the extraction is converted into a relative ratio value for each peak area of the 4 ° brix ginseng extract as shown in Table 1 below.
  • Table 1 LC value obtained by reflux extraction (mg / g 4 ⁇ brix extract) Rb1 Rc Rb2 Rd Rg3 (s) Rg3 (r) Rk1 Rg5 LC value 1.51 1.10 1.27 0.23 - - - -
  • the crude ginseng extract obtained in step 1 was cooled to room temperature or cold bath and then filtered to obtain a filtrate, and the filtrate was concentrated under reduced pressure at 50 ° C. or lower to prepare a concentrate of 20 ° brix or higher.
  • Step 3 Fraction of Substrate Ginsenosides (Ginsenosides Rb1, Rb2, Rc, Rd) from Concentrate
  • the saponin component was adsorbed by passing through the adsorption resin Diaion HP-20 resin. Then, distilled water of about 5 times the resin volume was continuously passed to remove non-saponin-based components. 50 to 100 v / v% alcohol is passed through a volume of 5 to 10 times through a resin in which the non-saponin-based component is removed and only the saponin-based component is adsorbed to elute only the saponin-based component. Cenoside fractions were obtained.
  • Substrate ginsenoside fraction eluted in step 3 was concentrated under reduced pressure below 50 °C. Quantitative values of the substrate ginsenoside fractions are shown in Table 2 below.
  • the pH of the fraction obtained in the fourth step is adjusted to pH 2 to 3 using water and citric acid, and treated for 2 hours using a temperature in the range of 95 ⁇ 121 °C and pressure of 1 ⁇ 2Kpa, preferably 1.5Kpa
  • the substrate ginsenoside was converted to ginsenoside Rg 3, and the conversion was then concentrated under reduced pressure.
  • the change in the content of the saponin component according to the pH and temperature is shown in Table 3 below, and the unit of all saponin component values is mg / g 20 ⁇ brix extract.
  • the saponin component content measurement of Table 3 below was made by converting the standard curve into each saponin standard and calculating the peak area of each LC analysis.
  • a fifth step was carried out between the second and third steps of Example 1, and then the fourth step was carried out to make Comparative Example 3 as a material.
  • Rg3 was not detected at all in the saponin fraction using ginseng extract and the adsorptive resin, but in the sample treated with acid, high temperature and pressure according to the present invention, it was confirmed that Rg3 was enhanced by 5 to 20% by weight relative to the fraction weight.
  • Rg3 was enhanced by 5 to 20% by weight relative to the fraction weight.
  • Rg3 content of the material obtained by treatment at pH 2.5 and a temperature of 121 ° C. in the fifth step of Example 1 (Table 5) and pH 2, 2.5, 3 and 100 ° C., obtained at 121 ° C. in Comparative Example 3 Rg3 content of the material (Table 6) was as follows.
  • the ginsenoid Rb1-containing extract was fractionated after the acid / heat / pressure treatment to enhance the ginsenoside Rg3 and fractionated, thereby increasing the substrate ginsenoside content.
  • the conversion rate to Rg3 was high in the heat / pressure treatment method. Because of this, there is an excellent feature that can be expected to reduce the manufacturing process costs.
  • the memory improvement effect of the extract fractions enriched with ginsenoside Rg 3 component of the present invention was performed through an in vivo test using an animal model of memory loss induced by scopolamine.
  • the experimental animal model used mature male ICR mice (5 weeks old, 28 ⁇ 2g), and was raised in an animal room controlled by temperature and humidity, and water and drink were freely consumed.
  • the control group was a mouse that did not receive any sample, and 30 minutes before the experiment, only 1 mg / kg of scopolamine was used as a comparison group.
  • the ginsenoside Rg3 augmented fraction of the present invention was first administered orally once for each concentration of 25, 50, and 100 mg / kg, and manually administered using a manual evacuation box for the experimental group administered 1 mg / kg of scopolamine 30 minutes before the laboratory. Evasion tests were performed.
  • the passive evacuation box is divided into a light room and a dark room, and a box provided with a device capable of giving an electric shock on the floor. More specific passive avoidance test was performed as follows.
  • the animals were placed in the brightly lit compartments, and after 10 seconds of search time the gillotin doors were opened to enter the dark compartments (except animals that do not enter the dark side within 120 seconds after the guillotine doors are excluded from the experiment). Let). The time from the opening of the guillotine door to the dark side of the animal was measured. When the animals entered the dark side, the guillotine door was closed and a 0.5 mA electric shock was applied for 3 seconds. After 24 hours, the animals were placed in the light compartment again, and after 20 seconds of search time, the guillotin door was opened to allow access to the dark compartment. Latency time (retention time) for all four rounds to the dark side was measured up to 300 seconds.
  • the improvement of memory was evaluated based on the change in activity based on the latency time in acquisition trial on the first day of the experiment and the latency time in retention trial on the second day of the experiment.
  • the measurement results are shown in Figure 4 to obtain the average value of 10 experimental animals of each group.
  • the control group was a mouse to which no sample was administered, and 30 minutes before the experiment, only 1 mg / kg of scopolamine was used as a comparison group.
  • Ginsenoside Rg3 augmented fraction of the present invention was first administered orally, and the test group was administered with an underwater labyrinth apparatus to the test group administered 1 mg / kg of scopolamine 30 minutes before the lab.
  • the experimental apparatus used for the underwater maze experiment was to attach four signs of stars, squares, triangles, and circles at equal intervals to a circular water tank (90 cm in diameter and 45 cm in height), and a platform of 29 cm height under the double star. Water was filled up to 1 cm above the platform and the water was clouded using water temperature (24 ⁇ 1 °C) and food coloring to make the platform invisible from the surface of the water.
  • the animals were placed in one compartment of the water tank and the time to reach the platform was measured for 60 seconds. After 30 seconds, the same experiment was put down in another location and the time to reach the platform was measured for 60 seconds. The above process was carried out for 5 days with different positions of laying down. On the fifth day, the platform was removed, the platform was placed on the first day, and the time stayed in the compartment where the platform was located was measured for 60 seconds.
  • the ginsenoside Rg3 augmentation fraction in the underwater maze experiments as shown in Figure 5 when the scopolamine administration time increased significantly compared to the control group (5 days control 14.4 seconds, scopolamine treatment group 42.4 seconds ),
  • the ginsenoside Rg3 augmented fraction showed memory improving efficacy in the treatment group on the 5th day of the underwater maze experiment (scopolamine 41.4 sec, 50 mg / kg 23.1 sec, 200 mg / kg 25.9 sec). It was interpreted that the memory lowered by scopolamine was improved by the ginsenoside Rg3 augmented fraction.
  • the present invention provides a novel method of increasing the ginsenoside Rg3 content by heat, pressure, and acid treatment of ginseng extract, and contains an extract fraction of the ginsenoside Rg3 content obtained according to the method as an active ingredient. It is a very useful invention in the health functional food industry or biopharmaceutical industry because it has an excellent effect of providing a health functional food for improving memory or concentration or a pharmaceutical composition for preventing and treating memory or concentration decline.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Provided are: an extract fraction with an increased content of ginsenoside RG3 by extracting ginseng with water or ethanol, eluting the obtained extract on an adsorption resin to obtain a substrate ginsenoside extract fraction, and treating the obtained extract fraction with heat, pressure and a pH of predetermined conditions; a dietary supplement composition for improving memory or concentration; and a pharmaceutical composition for preventing and treating lapse of memory or concentration, containing the extract fraction as an active ingredient.

Description

인삼유래의 진세노사이드 RG3의 함량이 증강된 추출분획물을 유효성분으로 함유하는 기억력 또는 집중력 증진용 조성물Memory or concentration-enhancing composition containing extract fractions with enhanced content of ginsenoside RG3 derived from ginseng as active ingredients
본 발명은 인삼유래의 진세노사이드 Rg3 함량이 증강된 추출분획물의 제조방법 및 이를 유효성분으로 함유하는 기억력 또는 집중력 증진용 조성물에 관한 것이다. The present invention relates to a method for preparing an extract fraction of which ginsenoside Rg3 content derived from ginseng is enhanced and a composition for enhancing memory or concentration containing the same as an active ingredient.
인삼(Panax ginseng C.A. Mayer)은 식물학적으로 오갈피나무과(Araliaceae) 인삼속에 속하는 식물로써, 중국에서는 기원전부터 약용으로 사용되었고, 국내에서는 삼국시대부터 인삼을 교역, 약용으로 사용되어 왔으며, 현재까지도 여러 분야에 한약재나 건강식품으로 널리 사용 중에 있다.Ginseng (Panax ginseng CA Mayer) is botanically belonging to the genus Araliaceae ginseng, which has been used for medicinal purposes in China since BC, and has been used for trade and medicinal use in Korea since the Three Kingdoms. It is widely used as a herbal medicine or health food.
인삼에는 진세노사이드 (ginsenoside)라는 프로사포닌이 약 3 내지 6% 함유되어 있고 상기 진세노사이드는 인삼의 대표적인 생리활성 물질로서 약 33종의 진세노사이드가 보고되어 있다. 인삼의 진세노사이드는 고분자 구성성분과 연결되어 있어서 섭취 후 체내 흡수가 용이하지 않아 장내에 서식하는 미생물에 의해 분해되 후에 체내로 흡수된다. 즉, 진세노사이드에 결합된 당이 분해된 진세노사이드 형태가 최종적으로 체내에 흡수되고 진세노사이드 각각이 갖는 생리활성을 나타내는 형태인것이다. Ginseng contains about 3 to 6% of ginsenosides called ginsenosides, and about 33 kinds of ginsenosides have been reported as ginsenosides. Ginsenosides of ginseng are linked to high molecular weight components, which are not easily absorbed by the body after ingestion. That is, the ginsenoside form in which the sugar bound to the ginsenoside is decomposed is finally absorbed into the body and exhibits the physiological activity of each of the ginsenosides.
인삼에 있어서 미량성분인 진세노사이드 Rg3, Rh1, Rh2 등은 암예방 작용, 암세포 성장 억제작용, 혈압강하 작용, 뇌신경세포 보호작용, 항혈전 작용, 항산화 작용 등의 뛰어난 효과가 보고되어 있다. 상기 진세노사이드 Rg3, Rh1, Rh2 등은 수삼이나 인삼에는 검출되지 않는 성분으로, 상기 성분들은 수삼에 함유되어 있는 진세노사이드 Rb1, Rb2, Rc, Rd, Rg1, Re 등이 가공 과정중에 열 또는 압력 등에 의하여 전환되어 생성된다(박만기 등, 새로운 가공 인삼(仙蔘)의 성분 분석, 제 46회 추계 대한약학회 학술대회, 1997). Trace ginsenosides Rg3, Rh1, Rh2, etc. in ginseng have been reported to have excellent effects such as cancer prevention, cancer cell growth suppression, blood pressure lowering, cerebral nerve cell protection, antithrombotic action, and antioxidant action. The ginsenosides Rg3, Rh1, Rh2 and the like are not detected in ginseng or ginseng, and the components are ginsenosides Rb1, Rb2, Rc, Rd, Rg1, Re, etc. contained in the ginseng during heat or It is converted and produced by pressure (Park Man-Gi et al., Ingredient analysis of new processed ginseng, 46th Fall Conference of Korean Pharmaceutical Society, 1997).
수삼의 가장 대표적인 가공형태인 홍삼은 수삼을 물로 깨끗하게 세척하고, 일정한 용기에 넣어 가열된 수증기를 이용하여 크기에 따라 일정시간 찐 후, 이를 1차로 열풍건조하고, 이 후부터는 태양열 등 기타 방법으로 전체 수분 함량이 12.5 내지 13.5 % 정도 될 때까지 건조하는 방법으로 가공된다. 이러한 증삼 및 건조과정을 통해 말로닌 진세노사이드 (malonyl ginsenoside)의 말로닐기의 제거, 글라이코실기의 이탈 및 히드록시기의 이성체화 등의 반응이 일어나 수삼에서는 검출되지 않는 상기 진세노사이드 Rg3, Rh1, Rh2 등과 같은 홍삼 특유의 사포닌 성분들이 만들어 진다(Liquid chromatographic determination of less polar ginsenosides in processed ginseng. J. of Chromatogr. A, 921: 335-339, 2001). 그러나, 이러한 홍삼의 제조과정은 시간 및 비용이 많이 소모되는 비효율적인 공정으로서 홍삼의 대중화를 저해하는 요인이 되고 있다.Red ginseng, the most representative processed form of fresh ginseng, is washed clean with water, steamed for a certain period of time using heated steam in a certain container, and then dried by hot air firstly. Processed by drying until the content is about 12.5 to 13.5%. The ginsenosides Rg3, Rh1, which are not detected in fresh ginseng due to reactions such as removal of malonyl group of malonyl ginsenoside, desorption of glycosyl group and isomerization of hydroxy group through such red ginseng and drying process Red ginseng-specific saponin components such as Rh2 are produced (Liquid chromatographic determination of less polar ginsenosides in processed ginseng. J. of Chromatogr. A, 921: 335-339, 2001). However, the manufacturing process of the red ginseng is an inefficient process that consumes a lot of time and money, and has become a factor that inhibits the popularization of red ginseng.
최근의 통계청 보고에 의하면 1995년 5.9%를 차지하던 65세 이상의 노령 인구가 2000년대부터 급속히 증가하는 추세를 보이고 있고, 2020년에는 15.6%, 2030년에는 24.3%에 이를 것으로 추정되며, 이와 같이 평균 수명이 증가되는 현대 사회에서 인지 능력과 기억력은 학습이 중요한 청소년에서부터 뇌기능 저하가 나타나는 노인에 이르기까지 중요한 관심 대상이 되고 있다. According to a recent report by the National Statistical Office, the elderly population aged 65 or older, which accounted for 5.9% in 1995, has been increasing rapidly since the 2000s, and is expected to reach 15.6% in 2020 and 24.3% in 2030. In modern societies with increased lifespan, cognitive and memory are of great interest, from adolescents for whom learning is important to the elderly with brain dysfunction.
사람의 인지능력과 기억력과 같은 뇌기능의 저하는 모든 연령층에서 다양한 문제를 일으킬 수 있으며, 특히 노인층의 경우 치매와 같은 뇌 손상으로 인한 정상적인 생활이 불가능할 뿐만 아니라, 의학/사회/경제적 측면 전반에 걸쳐있는 국가적 중요 문제로 인식되어야 하며 시급히 해결하여야 할 중대한 국민보건 문제일 뿐만 아니라 기억력 및 집중력과 같은 뇌기능은 발병 이후 치료보다는 예방이 더욱 중요한 영역이어서, 뇌기능을 강화할 수 있는 물질의 개발은 절박한 상황에 이르렀다. Degradation of brain function, such as human cognition and memory, can cause a variety of problems in all age groups, especially for the elderly, not only normal life due to brain damage such as dementia, but also across medical, social and economic aspects. It is not only a serious national health problem that must be recognized as a national important problem that needs to be solved urgently, but also brain function such as memory and concentration are more important areas of prevention than treatment after the onset, so the development of substances that can strengthen brain function is urgent. Reached.
따라서, 본 발명자들은 기억력 또는 집중력 저하 개선, 예방 및 치료를 위하여 인삼 분획 추출물을 연구를 수행하였고 특히, 뇌 기능강화에 뛰어난 효과를 보이는 미량성분 진세노사이드 Rg3 성분이 증대된 인삼분획추출물 제조방법 및 상기 추출물을 유효성분으로 함유하는 기억력 또는 집중력의 저하를 예방 또는 개선용 조성물을 발명하기에 이르렀다.Therefore, the present inventors studied ginseng fraction extract for improving, preventing and treating memory or concentration decrease, and in particular, a method for preparing ginseng fraction extract with an increased trace component ginsenoside Rg3 component showing an excellent effect on enhancing brain function. The inventors have invented a composition for preventing or improving a decrease in memory or concentration which contains the extract as an active ingredient.
본 발명의 목적은, 진세노사이드 Rg3 함량이 증강된 추출분획물을 보다 경제적 또는 효율적으로 수득하는 방법을 제공하는 데 있다.It is an object of the present invention to provide a method for more economically or efficiently obtaining an extract fraction with enhanced ginsenoside Rg3 content.
본 발명의 다른 목적은, 진세노사이드 Rg3 함량이 증강된 추출분획물을 유효성분으로 함유하는 기억력 또는 집중력 개선용 건강기능성식품 조성물을 제공하는 데 있다.Another object of the present invention is to provide a health functional food composition for improving memory or concentration which contains an extract fraction of ginsenoside Rg3 content as an active ingredient.
본 발명의 또 다른 목적은, 진세노사이드 Rg3 함량이 증강된 추출분획물을 유효성분으로 함유하는 기억력 또는 집중력 감퇴 예방 및 치료용 약학적 조성물을 제공하는 데 있다.Still another object of the present invention is to provide a pharmaceutical composition for preventing and treating memory loss or concentration loss, which contains an extract fraction of which ginsenoside Rg3 content is enhanced as an active ingredient.
본 발명의 상기 목적은 추출 용매로 물 또는 주정을 사용하여 인삼 추출물을 수득하는 단계와; 흡착 수지를 이용하여 상기 추출물에서 기질 진세노사이드를 분획하는 단계와; 상기 기질 진세노사이드 분획물을 pH 2 내지 3으로 조정한 후에 95 내지 121 ℃ 범위의 온도 및 1 내지 2Kpa 범위의 압력으로 가공하여 진세노사이드 Rg3 함량이 증강된 추출분획물을 수득하는 단계를 통하여 달성하였다.The object of the present invention is to obtain a ginseng extract using water or alcohol as an extraction solvent; Fractionating the substrate ginsenoside from the extract using an adsorptive resin; The substrate ginsenoside fraction was adjusted to pH 2-3 and then processed to a temperature ranging from 95 to 121 ° C. and a pressure ranging from 1 to 2 Kpa to obtain an extract fraction with enhanced ginsenoside Rg3 content. .
본 발명은 물과 주정만을 사용하여 안정성이 증가되고 추출 시간 단축으로 인한 제조 임가공비가 절감된 진세노사이드 Rg3 함량이 증강된 추출분획물 제조방법을 제공하는 효과가 있다.The present invention has an effect of providing a method for producing an extract fraction with enhanced ginsenoside Rg3 content using only water and alcohol to increase the stability and to reduce the manufacturing process cost due to the reduction of extraction time.
이 밖에도, 본 발명은, 진세노사이드 Rg3 함량이 증강된 추출분획물을 유효성분으로 함유하는 기억력 또는 집중력 개선용 건강기능성식품 조성물과 기억력 또는 집중력 감퇴 예방 및 치료용 약학적 조성물을 제공하는 뛰어난 효과가 있다.In addition, the present invention has an excellent effect of providing a health functional food composition for improving memory or concentration and a pharmaceutical composition for preventing and treating memory loss or concentration loss, which contains an extract fraction with increased ginsenoside Rg3 content as an active ingredient. have.
도 1은 본 발명 진세노사이드 Rg3 함량이 증강된 추출분획물의 전체 제조공정을 나타낸 모식도이다.Figure 1 is a schematic diagram showing the overall manufacturing process of the extract fraction enhanced ginsenoside Rg3 content of the present invention.
도 2는 종래의 인삼, 홍삼 추출물의 HPLC 크로마토그램이다.2 is an HPLC chromatogram of conventional ginseng and red ginseng extract.
도 3는 본 발명 진세노사이드 Rg3 함량이 증강된 추출분획물의 HPLC 크로마토그램을 나타낸 도이다.Figure 3 is a diagram showing the HPLC chromatogram of the extract fraction enhanced ginsenoside Rg3 content of the present invention.
도 4는 본 발명 진세노사이드 Rg3 함량이 증강된 추출분획물의 공간 학습 능력에 미치는 효과를 나타내는 결과도이다.Figure 4 is a result showing the effect of the ginsenoside Rg3 content of the present invention on the spatial learning ability of the enhanced extract fraction.
도 5는 본 발명 진세노사이드 Rg3 함량이 증강된 추출분획물의 기억력 개선에 미치는 효과를 나타내는 결과도이다.5 is a result showing the effect of the ginsenoside Rg3 content of the present invention to improve the memory of the enhanced extract fractions.
본 발명에 있어서,‘인삼’이라는 용어는 단순히 수삼을 건조시킨 것만을 지칭하는 것이 아니며, 백삼, 수삼, 홍삼, 태극삼, 흑삼, 호정화인삼, 배양삼 등을 총괄하여 지칭하는 의미로 사용된다.In the present invention, the term “ginseng” does not simply refer to dried ginseng, but is used as a generic term for white ginseng, ginseng, red ginseng, taegeuk ginseng, black ginseng, stabilized ginseng, culture ginseng, and the like.
본 발명에 있어서, '기질 진세노사이드’라는 용어는 진세노사이드 Rg3의 제조를 위한 기질이 되는 진세노사이드 Rb1, Rb2, Rc 및 Rd 등을 모두 지칭하는 의미로 사용된다. In the present invention, the term 'substrate ginsenoside' is used to mean all of ginsenosides Rb1, Rb2, Rc and Rd, which are substrates for the preparation of ginsenoside Rg3.
본 발명에서는 추출 용매로 물 또는 주정을 사용한다. 따라서 유기 용매를 이용하는 종래의 방법과 달리, 본 발명의 제조방법에 의해 수득되는 본 발명 진세노사이드 Rg3 함량이 증강된 추출분획물은 식품·의약품으로 제조하는 데 있어 안전하게 사용가능하다. In the present invention, water or alcohol is used as the extraction solvent. Therefore, unlike the conventional method using an organic solvent, the extract fraction of the present invention ginsenoside Rg3 content obtained by the production method of the present invention can be safely used in the manufacture of food and pharmaceuticals.
또, 본 발명에 있어서 인삼으로부터 기질 진세노사이드를 추출하는 시간 및 온도는 기질 진세노사이드 성분이 파괴되지 않는 한 특별하게 제한되지 않으나, 바람직하게는 80℃에서 4시간씩 3회 추출한다. 그리고 흡착 수지는 기질 진세노사이드를 흡착시킬 수 있는 한 특별하게 제한되지는 않으나, 바람직하게는 다이아이온 HP20 흡착 수지(일본, 미쓰비스)이다. Further, in the present invention, the time and temperature for extracting the substrate ginsenoside from ginseng are not particularly limited as long as the substrate ginsenoside component is not destroyed, but is preferably extracted three times at 80 ° C. for 4 hours. The adsorbent resin is not particularly limited as long as it can adsorb the substrate ginsenoside, but is preferably a diion HP20 adsorbent resin (Mitsubishi, Japan).
본 발명에 따르면, 인삼 추출물을 다이아이온 HP20에 가한 후에, 수지 용적의 5배의 물을 이동상으로 사용하여 인삼 추출물중에서 비사포닌계 성분을 제거하고, 이어서 50 내지 100 v/v% 주정을 이동상으로 사용하여 기질 진세노사이드 성분을 용출시켜서 본 발명 Rg3 성분이 증강된 추출물을 제조하기 위한 기질로 사용하였다. According to the present invention, after adding ginseng extract to Diaion HP20, the non-saponin-based component is removed from the ginseng extract using 5 times the volume of resin as the mobile phase, and then 50 to 100 v / v% alcohol is used as the mobile phase. Elution of the substrate ginsenoside component was used as a substrate for preparing an extract of which the Rg3 component of the present invention is enhanced.
본 발명에 따르면, 수득된 기질 진세노사이드 분획물은 산에 의해 pH 2 내지 3으로 조정되고, 이어서 95 내지 121 ℃ 에서 1 내지 2 Kpa, 바람직하게는 1.5KPa로 처리한다. 산의 종류는 특별하게 제한되지는 않으며, 바람직한 산의 종류는 구연산, 아세트산 등이다. 상기 처리에 의해서 기질 진세노사이드가 진세노사이드 Rg3로 전환된다.According to the invention, the obtained substrate ginsenoside fraction is adjusted to pH 2-3 by acid, followed by treatment at 95-121 ° C. with 1-2 Kpa, preferably 1.5 KPa. The kind of acid is not particularly limited, and a preferred kind of acid is citric acid, acetic acid and the like. The treatment converts the substrate ginsenosides to ginsenoside Rg3.
본 발명에 따라 제조된 진세노사이드 Rg3 함량이 증강된 추출분획물을 유효성분으로 함유하는 약학적 조성물을 제공한다. 상기 추출분획물은 바람직하게 약학적 조성물 총 중량에 대하여 0.1내지 99 중량%를 함유하는 것으로 한다.It provides a pharmaceutical composition containing the extract fraction of the ginsenoside Rg3 content prepared according to the present invention as an active ingredient. The extract fraction preferably contains 0.1 to 99% by weight relative to the total weight of the pharmaceutical composition.
본 발명에 따른 상기 약학적 조성물은 약학적으로 허용 가능한 담체를 포함하여 다양한 형태, 예를 들어 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구용 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화될 수 있다. 특히 바람직하게는 경구용 제형으로 제제화될 수 있다.The pharmaceutical composition according to the present invention may be prepared in various forms including pharmaceutically acceptable carriers, for example, oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and the like. It may be formulated in the form of sterile injectable solutions. Especially preferably, it may be formulated in an oral dosage form.
상기 약제학적으로 허용 가능한 담체는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한다. 또한, 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 포함한다. 경구용 고형 제제는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 포함할 수 있으며, 마그네슘 스테아레이트, 탈크 같은 윤활제 등을 포함할 수 있다. 경구용 액상 제제는 현탁제, 내용액제, 유제, 시럽제 등을 포함하며, 물, 리퀴드 파라핀 등의 희석제, 습윤제, 감미제, 방향제, 보존제 등을 포함할 수 있다. 비경구용 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제를 포함하며, 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르류 등을 포함한다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로 젤라틴 등이 사용될 수 있다.The pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. Also included are diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like. Oral solid preparations include tablets, pills, powders, granules, capsules and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or lactose. ), Gelatin, and the like, and may include a lubricant such as magnesium stearate, talc, and the like. Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include water, diluents such as liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like. Parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and ethylol. Injectable esters such as late and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycero gelatin and the like can be used.
본 발명은 본 발명에 따라 제조된 진세노사이드 Rg3 함량이 증강된 추출분획물을 유효성분으로 함유하는 약학적 조성물을 제공한다. 상기 추출분획물은 바람직하게 건강기능성식품 조성물 총 중량에 대하여 0.1내지 99 중량%를 함유하는 것으로 한다.The present invention provides a pharmaceutical composition containing the extract fraction of the ginsenoside Rg3 content prepared according to the present invention as an active ingredient. The extract fraction preferably contains 0.1 to 99% by weight based on the total weight of the health functional food composition.
본 발명의 식품 조성물은 건강기능식품으로서 사용될 수 있다. 상기 "건강기능식품"이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The food composition of the present invention can be used as a dietary supplement. The term "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functionality" refers to the structure of the human body. And ingestion for the purpose of obtaining nutrients for function or for obtaining useful effects in health uses such as physiological actions.
본 발명의 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 "식품 첨가물"로 서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The food composition of the present invention may include a conventional food additives, and the suitability as the "food additives", unless otherwise specified, in accordance with the General Regulations and General Test Methods of the Food Additives approved by the Food and Drug Administration Judge according to the standards and standards for the item.
상기 "식품 첨가물 공전"에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.Examples of the items listed in the "Food Additives Revolution" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid, natural additives such as color pigments, licorice extract, crystalline cellulose, high color pigments, guar gum, And mixed preparations such as sodium L-glutamate, algae additives, preservatives and tar dyes.
캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질캅셀에 생약 추출물에 부형제 등의 첨가제와의 혼합물 또는 그의 입상물 또는 제피한 입상물을 충진하여 제조할 수 있으며, 연질 캅셀제는 생약 추출물에 부형제 등의 첨가제와의 혼합물을 젤라틴 등 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among the health functional foods in the form of capsules, the hard capsules may be prepared by filling a conventional hard capsule with a mixture of additives such as an excipient or the like, or granules or exfoliated granules thereof, and a soft capsule agent with an excipient, etc. It can be prepared by filling a mixture with an additive of a capsule base such as gelatin. The soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
환 형태의 건강기능식품은 생약 추출물에 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 적당한 제피제로 제피를, 또는 전분, 탈크 또는 적당한 물질로 환의를 입힐 수도 있다.The dietary supplement in cyclic form can be prepared by molding a mixture of excipients, binders, disintegrants, etc. in the herbal extracts in a suitable manner, and if necessary, the coating is carried out with white sugar or other suitable coating agent, or with starch, talc or a suitable substance. You may be greeted.
과립형태의 건강기능식품은 상기 생약 추출물에 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다. 본원 발명의 상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함한다 (대한약전 해설편, 문성사, 한국약학대학협의회, 제 5 개정판, p33-48, 1989).The health functional food in the form of granules may be prepared into granules in a suitable manner by mixing a mixture of an excipient, a binder, a disintegrant, and the like with the herbal extract, and may contain a flavoring agent, a copper, and the like as necessary. The term definitions of the excipients, binders, disintegrants, glidants, copulation agents, flavoring agents, etc. of the present invention are described in documents known in the art and include those having the same or similar functions. Sacrament, Korean College of Pharmacy, 5 revised edition, p33-48, 1989).
이하, 본 발명을 하기 실시예 및 실험예에 의해 더욱 구체적으로 설명한다. 그러나, 이들 실시예 및 실험예는 본 발명에 대한 이해를 돕기 위한 목적일 뿐이므로, 어떤 의미로든 본 발명의 범위가 이들에 의해 제한되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to the following Examples and Experimental Examples. However, these Examples and Experimental Examples are only for the purpose of helping the understanding of the present invention, and the scope of the present invention is not limited by them in any sense.
<실시예 1> 인삼 추출물의 제조 Example 1 Preparation of Ginseng Extract
제 1단계: 인삼, 홍삼, 미삼으로부터 추출물의 제조 First Step: Preparation of Extracts from Ginseng, Red Ginseng, and Misam
본 발명의 실험에 사용된 원료는 인삼의 잔뿌리 부분인 백미삼을 공시재료로하여 상기 원료100kg의 10배 (w/v)의 물을 넣고 80 ℃ 에서 4시간씩 3회 환류 추출하였다. 상기 추출에 의해 얻어진 성분의 액체 크로마토그래피(이하,‘LC’라 한다) 값은 하기 표 1에 나타낸 바와 같이 4˚brix 인삼추출물의 각각의 피크면적에 대한 상대적 비율값으로 환산한다.The raw material used in the experiment of the present invention was extracted by refluxing three times at 80 ° C. for 4 hours by adding 10 times (w / v) water of 100 kg of the raw material using white rice, which is a root root of ginseng, as a test material. The liquid chromatography (hereinafter referred to as "LC") value of the component obtained by the extraction is converted into a relative ratio value for each peak area of the 4 ° brix ginseng extract as shown in Table 1 below.
표 1 환류 추출결과 수득한 LC 값(mg/g 4˚brix extract)
Rb1 Rc Rb2 Rd Rg3(s) Rg3(r) Rk1 Rg5
LC 값 1.51 1.10 1.27 0.23 - - - -
Table 1 LC value obtained by reflux extraction (mg / g 4˚brix extract)
Rb1 Rc Rb2 Rd Rg3 (s) Rg3 (r) Rk1 Rg5
LC value 1.51 1.10 1.27 0.23 - - - -
제 2단계: 추출물로부터 농축물의 제조Step 2: Preparation of Concentrate from Extract
상기 1 단계에서 수득한 미삼 추출물을 상온 또는 저온 중탕 냉각한 후에 여과하여 여과액을 수득하였고 그 여과액을 50 ℃ 이하에서 감압 농축하여 20 °brix 이상의 농축물을 제조하였다.The crude ginseng extract obtained in step 1 was cooled to room temperature or cold bath and then filtered to obtain a filtrate, and the filtrate was concentrated under reduced pressure at 50 ° C. or lower to prepare a concentrate of 20 ° brix or higher.
제 3단계: 농축물로부터 기질 진세노사이드 (진세노사이드 Rb1, Rb2, Rc, Rd)의 분획 Step 3: Fraction of Substrate Ginsenosides (Ginsenosides Rb1, Rb2, Rc, Rd) from Concentrate
상기 2 단계에서 수득한 농축물에 5 배 용적의 물을 가하여 충분히 희석시킨 후, 흡착수지 다이아이온 HP-20 수지를 통과시킴으로써 사포닌 성분을 흡착시켰다. 그 다음, 상기 수지 용적의 약 5 배의 증류수를 계속 통과시켜 비사포닌계 성분을 제거하였다. 비사포닌계 성분이 제거되고 사포닌계 성분만 흡착되어 있는 수지에 50~100 v/v% 주정을 5 내지 10배 부피로 통과시켜 사포닌계 성분만을 용출시켜 최종적으로 사포닌계 성분 즉, 본 발명 기질 진세노사이드 분획물을 수득하였다.After adding 5 times the volume of water to the concentrate obtained in step 2 and diluting sufficiently, the saponin component was adsorbed by passing through the adsorption resin Diaion HP-20 resin. Then, distilled water of about 5 times the resin volume was continuously passed to remove non-saponin-based components. 50 to 100 v / v% alcohol is passed through a volume of 5 to 10 times through a resin in which the non-saponin-based component is removed and only the saponin-based component is adsorbed to elute only the saponin-based component. Cenoside fractions were obtained.
제 4단계: 분획물의 냉각, 여과 및 농축 Fourth Step: Cooling, Filtration and Concentration of Fractions
상기 3 단계에서 용출된 기질 진세노사이드 분획물을 50 ℃ 이하에서 감압 농축하였다. 기질 진세노사이드 분획물의 정량분석 값은 하기 표 2에 나타냈다.Substrate ginsenoside fraction eluted in step 3 was concentrated under reduced pressure below 50 ℃. Quantitative values of the substrate ginsenoside fractions are shown in Table 2 below.
분석결과, 인삼 추출물 자체에는 Rg3가 전혀 검출되지 않았다.As a result, no ginseng was detected in the ginseng extract itself.
표 2 기질 진세노사이드 분획물의 정량분석치(mg/g 20˚brix extract)
Rb1 Rc Rb2 Rd Rg3(s) Rg3(r) Rk1 Rg5
Control 7.07731 5.22527 6.65537 1.25209 - - - -
TABLE 2 Quantitative Analysis of Substrate Ginsenoside Fraction (mg / g 20˚brix extract)
Rb1 Rc Rb2 Rd Rg3 (s) Rg3 (r) Rk1 Rg5
Control 7.07731 5.22527 6.65537 1.25209 - - - -
제5단계: 분획물 중 진세노사이드 Rg3의 강화Step 5: Enhance Ginsenoside Rg3 in Fraction
상기 제4단계에서 수득한 분획물의 pH 를 물, 구연산을 이용하여 pH 2 내지 3으로 조정하고, 95 ~121 ℃ 범위의 온도 및 1 ~ 2Kpa, 바람직하게는 1.5Kpa의 압력을 이용하여 2시간 처리하여 기질 진세노사이드를 진세노사이드 Rg3로 전환시킨 후 그 전환물을 감압 농축하였다. 상기 pH 및 온도에 따른 사포닌 성분의 함량 변화를 하기 표 3에 나타냈으며, 모든 사포닌 성분 수치의 단위는 mg/g 20 ˚brix extract이다. The pH of the fraction obtained in the fourth step is adjusted to pH 2 to 3 using water and citric acid, and treated for 2 hours using a temperature in the range of 95 ~ 121 ℃ and pressure of 1 ~ 2Kpa, preferably 1.5Kpa The substrate ginsenoside was converted to ginsenoside Rg 3, and the conversion was then concentrated under reduced pressure. The change in the content of the saponin component according to the pH and temperature is shown in Table 3 below, and the unit of all saponin component values is mg / g 20˚brix extract.
하기 표 3의 사포닌 성분 함량측정은 각 사포닌 표준품으로 스탠다드커브를 작성하고 각각의 LC분석 피크면적을 계산하여 환산하여 나타냈다.The saponin component content measurement of Table 3 below was made by converting the standard curve into each saponin standard and calculating the peak area of each LC analysis.
표 3 본 발명 pH 및 온도 처리에 따른 Rg3의 함량변화(mg/g 20 ˚brix extract)
pH 온도(℃) Rb1 Rc Rb3 Rd Rg3(s) Rg3(r) Rg3 (합)
2 95 0.77 0.29 1.12 0.13 4.66 1.08 5.74
100 0.86 0.82 1.39 0.00 4.66 2.22 6.87
121 0.41 0.22 0.31 0.00 1.57 0.36 1.93
2.5 95 0.85 0.79 1.56 1.12 5.47 2.40 7.87
100 7.91 5.62 1.42 1.57 1.52 1.02 2.55
121 0.42 0.26 1.02 0.70 5.53 2.56 8.09
3 95 9.42 6.75 0.00 1.71 1.15 0.77 1.92
100 9.01 6.50 0.00 1.73 1.14 0.77 1.92
121 3.23 2.73 2.15 1.25 4.83 3.35 8.18
TABLE 3 Change of Rg3 content according to pH and temperature treatment of the present invention (mg / g 20 ˚brix extract)
pH Temperature (℃) Rb1 Rc Rb3 Rd Rg3 (s) Rg3 (r) Rg3 (sum)
2 95 0.77 0.29 1.12 0.13 4.66 1.08 5.74
100 0.86 0.82 1.39 0.00 4.66 2.22 6.87
121 0.41 0.22 0.31 0.00 1.57 0.36 1.93
2.5 95 0.85 0.79 1.56 1.12 5.47 2.40 7.87
100 7.91 5.62 1.42 1.57 1.52 1.02 2.55
121 0.42 0.26 1.02 0.70 5.53 2.56 8.09
3 95 9.42 6.75 0.00 1.71 1.15 0.77 1.92
100 9.01 6.50 0.00 1.73 1.14 0.77 1.92
121 3.23 2.73 2.15 1.25 4.83 3.35 8.18
비교예 1Comparative Example 1
백미삼 100 kg에 10배(w/v)의 물 또는 주정을 넣고 80 ℃ 에서 4시간씩 3회 환류 추출하여 얻어진 백미삼 추출물을 비교예 1로 하였다.10 g (w / v) of water or spirit was added to 100 kg of white rice ginseng, and the white rice ginseng extract obtained by reflux extraction three times for 4 hours at 80 ° C. was used as Comparative Example 1.
비교예 2Comparative Example 2
실시예 1의 제3단계에서 수득된 분획물을 비교예 2로 하였다.The fraction obtained in the third step of Example 1 was referred to as Comparative Example 2.
비교예 3Comparative Example 3
실시예 1의 제2단계와 제3단계 사이에 제5단계를 실시하고, 이어서 제4단계를 실시하여 수득된 물질을 비교예 3으로 하였다.A fifth step was carried out between the second and third steps of Example 1, and then the fourth step was carried out to make Comparative Example 3 as a material.
실험예 1 : 본 발명 진세노사이드 Rg 3 증강 추출분획물의 Rg 3 함량분석Experimental Example 1 Analysis of Rg 3 Content of Ginsenoside Rg 3 Enriched Extract Fraction of the Present Invention
상기 실시예 1, 비교예 1과 2 각각에서 얻어진 물질을 HPLC 분석하여 진세노사이드 Rg3의 함량을 측정하고, 그 결과를 하기 표 4에 기재하였다.HPLC analysis of the material obtained in each of Example 1, Comparative Examples 1 and 2 to determine the content of ginsenoside Rg3, the results are shown in Table 4 below.
분석결과, 인삼 추출물과 흡착수지를 이용한 사포닌 분획물에서는 Rg3가 전혀 검출되지 않았으나, 본 발명에 따라 산, 고온, 압력처리를 한 시료에서는 Rg3가 분획물 중량 대비 무려 5 ~ 20중량%까지 증강된 것을 확인할 수 있었다.As a result, Rg3 was not detected at all in the saponin fraction using ginseng extract and the adsorptive resin, but in the sample treated with acid, high temperature and pressure according to the present invention, it was confirmed that Rg3 was enhanced by 5 to 20% by weight relative to the fraction weight. Could.
표 4 진세노사이드 Rg3의 함량비교
실험 물질 진세노사이드Rg3 함량
비교예 1(백미삼 추출물) -
비교예 2(흡착수지를 이용한 사포닌 분획물) -
실시예 1(본 발명의 진세노사이드 Rg3 증강분획물) 5 ~ 20 중량%
Table 4 Content Comparison of Ginsenoside Rg3
Experimental substance Ginsenoside Rg3 Content
Comparative Example 1 (white rice extract) -
Comparative Example 2 (Saponin Fraction Using Adsorbent Resin) -
Example 1 (ginsenoside Rg3 augmented fraction of the present invention) 5-20 wt%
실험예 2: 산, 온도, 압력 처리조건에 따른 본 발명 본 발명 진세노사이드 Rg 3 증강 추출분획물의 Rg 3 함량분석 Experimental Example 2 Analysis of Rg 3 Content of Ginsenoside Rg 3 Enriched Extract Fraction of the Invention According to Acid, Temperature and Pressure Treatment Conditions
상기 실시예 1의 제5단계에서 pH 2.5 및 온도 121℃로 처리하여 수득된 물질의 Rg3 함량(표 5) 및 비교예 3에서 pH 2, 2.5, 3 및 100℃, 121℃로 처리하여 수득된 물질의 Rg3 함량(표 6)은 하기와 같았다.Rg3 content of the material obtained by treatment at pH 2.5 and a temperature of 121 ° C. in the fifth step of Example 1 (Table 5) and pH 2, 2.5, 3 and 100 ° C., obtained at 121 ° C. in Comparative Example 3 Rg3 content of the material (Table 6) was as follows.
표 5 분획 후 산, 압력 및 열처리에 따른 본 발명 진세노사이드 Rg 3 증강 추출분획물의 Rg3 함량
Rg3(s+r)(mg/g extract) 중량대비Rg3(s+r)함량(mg/50 g extract)
pH 2.5, 121℃ 상등액 2.362 3716.954
펠렛(pellet) 283.587
Table 5 Rg3 content of ginsenoside Rg3 enhanced extract fraction of the present invention according to acid, pressure and heat treatment after fractionation
Rg3 (s + r) (mg / g extract) Rg3 (s + r) content by weight (mg / 50 g extract)
pH 2.5, 121 ℃ Supernatant 2.362 3716.954
Pellet 283.587
표 6 산 및 온도 처리 후 분획하는 조건에 따른 본 발명 진세노사이드 Rg 3 증강 분획물의 Rg3 함량
Rg3(s+r)(mg/g extract) Total Rg3(s+r) 함량 (상등액+pellet)(mg/50 g extract)
pH 2, 100℃ 상등액 1.043 2601.310
pellet 0.358
pH 2, 121℃ 상등액 0.757 3151.421
pellet 1.632
pH 2.5, 121℃ 상등액 1.064 3072.726
Table 6 Rg3 content of ginsenoside Rg3 enhanced fraction of the present invention according to the conditions of fractionation after acid and temperature treatment
Rg3 (s + r) (mg / g extract) Total Rg3 (s + r) content (supernatant + pellet) (mg / 50 g extract)
pH 2, 100 ℃ Supernatant 1.043 2601.310
pellet 0.358
pH 2, 121 ℃ Supernatant 0.757 3151.421
pellet 1.632
pH 2.5, 121 ℃ Supernatant 1.064 3072.726
상기 결과에서 알 수 있듯이, 진세노이드 Rb1 함유 추출물을 산/열/압력을 처리하여 진세노사이드 Rg3를 강화한 후에 분획시키는 방법보다, 진세노이드 Rb1 함유 추출물을 분획하여 기질 진세노사이드 함량을 높인 후에 산/열/압력 처리를 하는 방법에서 Rg3로의 전환률이 높았다. 이로 인해, 제조 임가공비의 절감효과가 기대될 수 있는 뛰어난 특징이 있다.As can be seen from the above results, the ginsenoid Rb1-containing extract was fractionated after the acid / heat / pressure treatment to enhance the ginsenoside Rg3 and fractionated, thereby increasing the substrate ginsenoside content. The conversion rate to Rg3 was high in the heat / pressure treatment method. Because of this, there is an excellent feature that can be expected to reduce the manufacturing process costs.
실험예 3: 본 발명 진세노사이드 Rg 3 증강 추출분획물의 기억력 개선효과 검정 Experimental Example 3: Memory improvement effect assay of the present ginsenoside Rg 3 enhanced extract fraction
본 발명 진세노사이드 Rg 3 성분이 증강된 추출분획물의 기억력 개선효과 검정은 스코폴라민에 의해 유도된 기억력 감퇴 동물모델을 이용한 생체내 실험(in vivo test)을 통하여 수행 하였다.The memory improvement effect of the extract fractions enriched with ginsenoside Rg 3 component of the present invention was performed through an in vivo test using an animal model of memory loss induced by scopolamine.
동물은 성숙한 웅성 ICR 생쥐(5주령, 28±2g) 이용하여 수동회피실험 및 수중미로시험을 확인하여 기억력 개선효과를 확인하였다.Animals were tested for manual evacuation and underwater maze using mature male ICR mice (5 weeks old, 28 ± 2g) to confirm their memory-improving effect.
실험동물 모델은 성숙한 웅성 ICR 생쥐(5주령, 28±2g)을 사용하며 온도와 습도가 조절되는 동물실에서 사육하고, 물과 음료는 자유롭게 섭취하도록 하였다. The experimental animal model used mature male ICR mice (5 weeks old, 28 ± 2g), and was raised in an animal room controlled by temperature and humidity, and water and drink were freely consumed.
<수동회피실험><Manual Evasion Experiment>
수동회피 실험에서 대조군은 아무런 시료를 투여하지 않은 마우스로 하였고, 실험 30분전에 스코폴라민을 1 mg/kg만을 투여하여 비교군으로 하였다. 본 발명 진세노사이드 Rg3 증대분획물을 먼저 25, 50, 100 mg/kg 농도 별로 각 1회 경구투여하고 실험실시 30분전에 스코폴라민을 1 mg/kg 투여한 실험군에 대해 수동회피상자를 이용한 수동회피검사를 수행하였다. 상기 수동회피상자는 밝은 방과 어두운 방으로 나누어지고, 바닥에는 전기충격을 줄 수 있는 장치가 구비된 상자이다. 보다 구체적인 수동회피검사는 다음과 같은 방법으로 수행하였다. In the passive avoidance experiment, the control group was a mouse that did not receive any sample, and 30 minutes before the experiment, only 1 mg / kg of scopolamine was used as a comparison group. The ginsenoside Rg3 augmented fraction of the present invention was first administered orally once for each concentration of 25, 50, and 100 mg / kg, and manually administered using a manual evacuation box for the experimental group administered 1 mg / kg of scopolamine 30 minutes before the laboratory. Evasion tests were performed. The passive evacuation box is divided into a light room and a dark room, and a box provided with a device capable of giving an electric shock on the floor. More specific passive avoidance test was performed as follows.
실험동물을 조명이 비춘 밝은 쪽 구획에 놓고 10초의 탐색시간 후 길로틴문 (gillotin door)이 열려 어두운 구획으로 들어갈 수 있게 하였다(길로틴문이 열린 후 120초 이내에 어두운 쪽으로 들어가지 않는 동물은 실험에서 제외시킨다). 길로틴문이 열린 후 동물이 어두운 쪽으로 들어갈 때까지의 시간을 측정하였다. 실험동물이 어두운 쪽으로 들어가면 길로틴문을 닫고 0.5 mA의 전기 충격을 3초 동안 가했다. 24시간 후 다시 실험동물을 밝은 쪽 구획에 놓고 20초의 탐색시간 후 길로틴문(gillotin door)을 열고 어두운 구획으로 들어갈 수 있게 하였다. 어두운 쪽으로 4발이 다 들어가는데 걸리는 시간(latency time: 머무름 시간)을 300초까지 측정하였다. 실험 1일째 어두운 구획으로 가는데 걸리는 시간 (Latency time in acquisition trial)을 근거로 활동성 변화, 실험 2일째 어두운 구획으로 가는데 걸리는 시간 (Latency time in retention trial)을 근거로 기억력 개선 효과를 평가 하였다. 상기 측정결과는 각 군의 10마리의 실험동물의 평균값을 구하여 도 4에 나타내었다. The animals were placed in the brightly lit compartments, and after 10 seconds of search time the gillotin doors were opened to enter the dark compartments (except animals that do not enter the dark side within 120 seconds after the guillotine doors are excluded from the experiment). Let). The time from the opening of the guillotine door to the dark side of the animal was measured. When the animals entered the dark side, the guillotine door was closed and a 0.5 mA electric shock was applied for 3 seconds. After 24 hours, the animals were placed in the light compartment again, and after 20 seconds of search time, the guillotin door was opened to allow access to the dark compartment. Latency time (retention time) for all four rounds to the dark side was measured up to 300 seconds. The improvement of memory was evaluated based on the change in activity based on the latency time in acquisition trial on the first day of the experiment and the latency time in retention trial on the second day of the experiment. The measurement results are shown in Figure 4 to obtain the average value of 10 experimental animals of each group.
실험결과, 도 4에 나타낸 바와 같이 스코폴라민을 주사하지 않은 대조군에 비하여 스코폴라민을 주사한 비교군에서 활동성에는 큰 변화가 없으나, 기억력이 현저하게 감소되는 것을 확인할 수 있었다. As a result, as shown in FIG. 4, there was no significant change in activity in the comparison group injected with scopolamine compared to the control group not injected with scopolamine, but it was confirmed that memory was significantly reduced.
한편, 본 발명 진세노사이드 Rg3 증대분획물 농도별로 25, 50, 100 mg/kg씩 각각 섭취시킨 실험군의 경우에는 스코폴라민에 의해 손상된 기억력이 25mg/kg 처리군부터 용량 의존적으로 유의성 있게 증가되어 기억력을 회복하는 것을 확인하였다. 상기 실험결과로부터 진세노사이드 Rg3 증대분획물은 기억력 손상의 예방 및 기억력 개선에 효과적인 것으로 확인되었다.On the other hand, in the experimental group ingested 25, 50, 100 mg / kg each by the concentration of the ginsenoside Rg3 augmented fraction of the present invention, memory capacity damaged by scopolamine significantly increased dose-dependently from the 25 mg / kg treatment group It was confirmed to recover. From the experimental results, it was confirmed that the ginsenoside Rg3 augmented fraction is effective for preventing memory impairment and improving memory.
<수동미로실험>Manual labyrinth experiment
수동미로 실험에서 대조군은 아무런 시료를 투여하지 않은 마우스로 하였고, 실험 30분전에 스코폴라민을 1 mg/kg만을 투여하여 비교군으로 하였다. 본 발명 진세노사이드 Rg3 증대분획물을 먼저 경구투여하고 실험실시 30분전에 스코폴라민을 1 mg/kg 투여한 실험군에 대해 수중미로실험 장치를 이용한 검사를 수행하였다. In the manual labyrinth experiment, the control group was a mouse to which no sample was administered, and 30 minutes before the experiment, only 1 mg / kg of scopolamine was used as a comparison group. Ginsenoside Rg3 augmented fraction of the present invention was first administered orally, and the test group was administered with an underwater labyrinth apparatus to the test group administered 1 mg / kg of scopolamine 30 minutes before the lab.
수중미로실험에 사용된 실험장치는 원형의 물 탱크(지름 90 cm, 높이 45cm)에 각각 별, 네모, 세모, 원의 네가지 표지를 같은 간격으로 붙이고 이중 별 아래에 29cm 높이의 플랫폼(platform)고 플랫폼보다 1cm 윗부분까지 물을 채우고 수온 (24 ± 1℃), 식용색소를 이용하여 물을 흐리게 하여 수면에서 플랫폼이 보이지 않게 하였다. The experimental apparatus used for the underwater maze experiment was to attach four signs of stars, squares, triangles, and circles at equal intervals to a circular water tank (90 cm in diameter and 45 cm in height), and a platform of 29 cm height under the double star. Water was filled up to 1 cm above the platform and the water was clouded using water temperature (24 ± 1 ℃) and food coloring to make the platform invisible from the surface of the water.
실험동물을 물 탱크의 한 구획에 내려놓고 플랫폼까지 찾아가는 시간을 60초 동안 측정하였다. 30초 후 다른 위치에 동일한 실험동물을 내려놓고 플랫폼까지 찾아가는 시간을 60초 동안 측정하였다. 위의 과정을 5일 동안 내려놓는 위치를 바꿔가며 실시하였다. 5일째 되는 날 플랫폼을 제거하고 첫째 날 내려놓았던 위치에 내려놓은 후 플랫폼이 위치했던 구획에 머문 시간을 60초 동안 측정하였다. The animals were placed in one compartment of the water tank and the time to reach the platform was measured for 60 seconds. After 30 seconds, the same experiment was put down in another location and the time to reach the platform was measured for 60 seconds. The above process was carried out for 5 days with different positions of laying down. On the fifth day, the platform was removed, the platform was placed on the first day, and the time stayed in the compartment where the platform was located was measured for 60 seconds.
실험결과, 도 5에 나타낸 바와 같이, 스코폴라민을 주사하지 않은 대조군의 경우에는 실험이 진행되면서 점차적으로 플랫폼을 찾아 탈출하는데 소요되는 시간(Escape latency)이 감소되었으나, 스코폴라민만을 주사한 비교군의 경우에는 실험이 진행되는 것과 상관없이 플랫폼을 찾아 탈출하는데 소요되는 시간(Escape latency)이 거의 일정한 것으로 확인되었다. 이는 스코폴라민에 의해 기억력이 손상되고, 상기 손상된 기억력이 회복되지 않았기 때문인 것으로 해석되었다.As shown in FIG. 5, in the case of the control group not injected with scopolamine, the time required for escaping the platform gradually decreased as the experiment proceeded, but compared with the injection of scopolamine only. In the case of the military, the escape latency was found to be almost constant regardless of the experiment being conducted. This was interpreted to be because memory was impaired by scopolamine and the impaired memory was not recovered.
한편, 수중미로실험에서 진세노사이드 Rg3 증대분획물는 도 5에서 보는 바와 같이 스코폴라민을 투여하면 플랫폼을 찾아가는 시간이 대조군에 비해 유의성 있게 증가하지만 (5일 대조군 14.4초, 스코폴라민 처치군 42.4초), 진세노사이드 Rg3 증대분획물는 수중미로실험 5일째 처치군에서 기억력 개선 효능을 나타내었다 (스코폴라민 41.4초, 50mg/kg 23.1초, 200mg/kg 25.9초). 이는 진세노사이드 Rg3 증대분획물에 의해 스코폴라민에 의해 저하된 기억력이 개선되었기 때문인 것으로 해석되었다.On the other hand, the ginsenoside Rg3 augmentation fraction in the underwater maze experiments, as shown in Figure 5 when the scopolamine administration time increased significantly compared to the control group (5 days control 14.4 seconds, scopolamine treatment group 42.4 seconds ), The ginsenoside Rg3 augmented fraction showed memory improving efficacy in the treatment group on the 5th day of the underwater maze experiment (scopolamine 41.4 sec, 50 mg / kg 23.1 sec, 200 mg / kg 25.9 sec). It was interpreted that the memory lowered by scopolamine was improved by the ginsenoside Rg3 augmented fraction.
본 발명은 인삼 추출물에 열, 압력, 산 처리를 하여 진세노사이드 Rg3 함량을 증대시키는 신규한 방법을 제공하고 상기 방법에 따라 수득한 진세노사이드 Rg3 함량이 증강된 추출분획물을 유효성분으로 함유하는 기억력 또는 집중력 개선용 건강기능성식품 또는 기억력 또는 집중력 감퇴 예방 및 치료용 약학적 조성물을 제공하는 뛰어난 효과가 있으므로 건강기능식품산업 또는 생물의약산업상 매우 유용한 발명이다.The present invention provides a novel method of increasing the ginsenoside Rg3 content by heat, pressure, and acid treatment of ginseng extract, and contains an extract fraction of the ginsenoside Rg3 content obtained according to the method as an active ingredient. It is a very useful invention in the health functional food industry or biopharmaceutical industry because it has an excellent effect of providing a health functional food for improving memory or concentration or a pharmaceutical composition for preventing and treating memory or concentration decline.

Claims (9)

  1. 인삼으로부터 진세노사이드 Rg3 함량이 증강된 추출물 분획물을 제조하는 방법에 있어서,In the method for preparing an extract fraction with enhanced ginsenoside Rg3 content from ginseng,
    추출 용매로 물 또는 주정을 사용하여 기질 진세노사이드 추출물을 인삼으로부터 수득하는 단계와; 상기 추출물을 흡착 수지에 흡착시켜 기질 진세노사이드 추출물을 분획하여 기질 진세노사이드 추출 분획물을 수득하는 단계와; 상기 추출 분획물을 산에 의해 pH 2 내지 3로 조정한 후에 95 내지 121 ℃ 범위의 온도 및 1 내지 2Kpa 범위의 압력으로 처리하는 단계를 포함하는 것을 특징으로 하는 제조방법.Obtaining the substrate ginsenoside extract from ginseng using water or alcohol as the extraction solvent; Adsorbing the extract on an adsorption resin to fractionate the substrate ginsenoside extract to obtain a substrate ginsenoside extract fraction; Adjusting said extract fraction to pH 2 to 3 with acid followed by a temperature in the range of 95 to 121 ° C. and a pressure in the range of 1 to 2 Kpa.
  2. 제 1항에 있어서, 상기 인삼은 백삼, 수삼, 홍삼, 태극삼, 흑삼, 호정화인삼 또는 배양삼으로 이루어진 군으로부터 선택되는 하나임을 특징으로 하는 제조방법.The method of claim 1, wherein the ginseng is one selected from the group consisting of white ginseng, ginseng, red ginseng, taegeuk ginseng, black ginseng, stabilized ginseng or cultured ginseng.
  3. 제 1항 또는 제 2항의 방법에 따라 수득된 것을 특징으로 하는 진세노사이드 Rg3 함량이 증강된 추출분획물.An extract fraction with enhanced ginsenoside Rg3 content, which is obtained according to the method of claim 1 or 2.
  4. 제 3항 기재의 추출분획물을 유효성분으로 함유하는 것을 특징으로 하는 기억력 또는 집중력 개선용 건강기능성식품 조성물. A health functional food composition for improving memory or concentration, comprising extracting the extract of claim 3 as an active ingredient.
  5. 제 4항에 있어서, 상기 조성물은 캅셀제, 환제, 과립제로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가지는 것을 특징으로 하는 건강기능성식품 조성물.The health functional food composition according to claim 4, wherein the composition has any one formulation selected from the group consisting of capsules, pills, and granules.
  6. 제 4항에 있어서, 상기 조성물은 식품학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함하는 것이 특징인 건강기능성식품 조성물.The health functional food composition of claim 4, wherein the composition further comprises a food acceptable carrier, excipient or diluent.
  7. 제 3항 기재의 추출분획물을 유효성분으로 함유하는 것을 특징으로 하는 기억력 또는 집중력 예방 및 치료용 약학적 조성물. A pharmaceutical composition for preventing or treating memory or concentration, characterized in that it contains the extract fraction of claim 3 as an active ingredient.
  8. 제 7항에 있어서, 상기 조성물은 정제, 환제, 산제, 과립제, 캅셀제, 현탁제, 내용액제, 유제, 시럽제, 멸균된 수용액, 비수성용제, 현탁제, 동결건조제제 및 좌제로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가지는 것을 특징으로 하는 약학적 조성물.8. The composition of claim 7, wherein the composition is selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, lyophilized preparations and suppositories. A pharmaceutical composition, characterized in that it has any one formulation.
  9. 제 7항에 있어서, 상기 조성물은 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함하는 것이 특징인 약학적 조성물.8. The pharmaceutical composition of claim 7, wherein the composition further comprises a pharmaceutically acceptable carrier, excipient or diluent.
PCT/KR2013/000337 2012-01-20 2013-01-16 Composition for improving memory or concentration containing extract fraction with increased content of ginseng-derived ginsenoside rg3 as active ingredient WO2013109051A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2012-0007043 2012-01-20
KR20120007043 2012-01-20
KR10-2012-0154126 2012-12-27
KR1020120154126A KR20130085935A (en) 2012-01-20 2012-12-27 A composition comprising an extract fraction having enhanced content of ginsenoside rg3 from ginseng radix for improving convergency and memory capacity

Publications (1)

Publication Number Publication Date
WO2013109051A1 true WO2013109051A1 (en) 2013-07-25

Family

ID=48799428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/000337 WO2013109051A1 (en) 2012-01-20 2013-01-16 Composition for improving memory or concentration containing extract fraction with increased content of ginseng-derived ginsenoside rg3 as active ingredient

Country Status (1)

Country Link
WO (1) WO2013109051A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2982376A4 (en) * 2013-04-02 2017-01-04 Amorepacific Corporation Composition for brain activation, comprising ginseng berry extract
KR20180064091A (en) * 2016-12-05 2018-06-14 한밭대학교 산학협력단 Manufacturing method of an extract enriched with ginsenoside Rg3 from red ginseng and food composition containing it
CN115120559A (en) * 2022-07-22 2022-09-30 江南大学 Method for improving embedding rate of ginsenoside Rg3 and CK and stability of nano emulsion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100228510B1 (en) * 1995-11-22 2000-03-15 손경식 A process for the preparation of ginsenoside Rg3 and/or Rg5
KR20020087787A (en) * 2001-05-16 2002-11-23 재단법인 한국인삼연초연구원 The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk
KR20050117793A (en) * 2004-06-11 2005-12-15 주식회사 유니젠 Ginseng composition for preventing or improving the lowering of concentration and memory capability
KR100805852B1 (en) * 2006-12-21 2008-02-21 한국식품연구원 Method of producing ginsenoside enforced ginseng and method of producing red ginseng employing the same
KR20110052940A (en) * 2009-11-13 2011-05-19 씨제이제일제당 (주) A process for preparing an extract fraction enriched with ginsenoside rg3 from ginseng radix

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100228510B1 (en) * 1995-11-22 2000-03-15 손경식 A process for the preparation of ginsenoside Rg3 and/or Rg5
KR20020087787A (en) * 2001-05-16 2002-11-23 재단법인 한국인삼연초연구원 The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk
KR20050117793A (en) * 2004-06-11 2005-12-15 주식회사 유니젠 Ginseng composition for preventing or improving the lowering of concentration and memory capability
KR100805852B1 (en) * 2006-12-21 2008-02-21 한국식품연구원 Method of producing ginsenoside enforced ginseng and method of producing red ginseng employing the same
KR20110052940A (en) * 2009-11-13 2011-05-19 씨제이제일제당 (주) A process for preparing an extract fraction enriched with ginsenoside rg3 from ginseng radix

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2982376A4 (en) * 2013-04-02 2017-01-04 Amorepacific Corporation Composition for brain activation, comprising ginseng berry extract
US10555983B2 (en) 2013-04-02 2020-02-11 Amorepacific Corporation Composition for brain activation, comprising ginseng fruit extract
KR20180064091A (en) * 2016-12-05 2018-06-14 한밭대학교 산학협력단 Manufacturing method of an extract enriched with ginsenoside Rg3 from red ginseng and food composition containing it
KR101962169B1 (en) * 2016-12-05 2019-07-18 한밭대학교 산학협력단 Manufacturing method of an extract enriched with ginsenoside Rg3 from red ginseng and food composition containing it
CN115120559A (en) * 2022-07-22 2022-09-30 江南大学 Method for improving embedding rate of ginsenoside Rg3 and CK and stability of nano emulsion

Similar Documents

Publication Publication Date Title
WO2010137846A2 (en) Composition for increasing the bioavailability of saponin
WO2017104966A1 (en) Composition containing saponins of panax ginseng as active ingredient
US7491414B2 (en) Anti-inflammatory substances extracted from Echinacea
WO2016003063A1 (en) Method for preparing ginseng polysaccharides for immune enhancement and ginseng polysaccharides for immune enhancement prepared by same preparation method
WO2018088869A1 (en) Method for preparing processed ginseng containing honey ingredients
WO2019083321A2 (en) Composition for antioxidation, anti-inflammation, or osteoclast differentiation inhibition
CN101554409A (en) Long pepper alkaloid and preparation method, preparation and application thereof
WO2018128408A1 (en) Pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy, comprising baicalein as active ingredient
WO2013109051A1 (en) Composition for improving memory or concentration containing extract fraction with increased content of ginseng-derived ginsenoside rg3 as active ingredient
CN108472325B (en) Composition for improving memory comprising petasites japonicus leaf extract
EP1843774B1 (en) Pulsatilla spp. extracts effective in brain function
WO2010053271A2 (en) Method for preparing extract fraction reinforced with ginsenosides rg1 or rb1 from ginseng
WO2018026103A1 (en) Composition for cell regeneration comprising ginseng floral axis extract
WO2016159524A2 (en) Composition for alleviating ovarian aging, containing ginseng berry extract
WO2016076607A2 (en) Pharmaceutical composition and health functional food, containing a red ginseng concentrate with enriched compound k component, for preventing and treating non-alcoholic fatty liver symptom
KR20130085935A (en) A composition comprising an extract fraction having enhanced content of ginsenoside rg3 from ginseng radix for improving convergency and memory capacity
WO2018190501A1 (en) Anti-inflammatory composition containing extract of ginseng flower stalk
KR101625474B1 (en) Manufacturing method for mass-production of ginsenoside Rh4
CN103142916B (en) Medicament for preventing and treating senile dementia and preparation method thereof
WO2018097348A1 (en) Hippophae rhamnoides l. beverage and preparation method therefor
WO2020091265A1 (en) Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male climacteric syndrome
KR101420135B1 (en) Extract of Eucommiae ulmoides for preventing or treating of learning or memory disorder, or dementia
WO2014133286A1 (en) Composition containing extracts of artemisia iwayomogi and curcuma longa as active ingredients for preventing, inhibiting, or treating obesity-related diseases
CN102228666B (en) Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease
CN104820029A (en) Content detection method for compound houttuynia cordata mixture

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13738918

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13738918

Country of ref document: EP

Kind code of ref document: A1